RDY - Amarin Corportion Plc: Now Compelling On Ex-U.S. Opportunity And Potential Barriers To Generic Competition
Amarin, Corp (AMRN) has been an extremely turbulent and highly visible stock over the years, with investors making and losing fortunes on the volatility generated by the interim successes and failures of the company's cardiovascular therapy, Vascepa. To be sure, this drug developer has successfully created a product that can benefit millions of people that have both high triglycerides and high cholesterol to improve their chances of avoiding major cardiovascular events (MACE). Despite major roadblocks by the FDA in the past, particularly a rescision of AMRN's special protocol assessment,